+0131U Hereditary breast cancer-hyphenrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) +0135U Hereditary gynecological cancer (eg, hered...
The FDA (2013) has stated that the cervical Pap smear has a known clinical benefit supported by extensive clinical studies over many years, and that its scientific ability to screen for cervical cancer is unquestioned. The nipple aspiration test has no such evidence supporting it. In addition, ...
Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am J Roentgenol. 2002;179(3):671-67712185042PubMedGoogle Scholar 37. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography ...
Comorbid diseases can affect breast cancer prognosis. We conducted a population-based study of Danish women diagnosed with a first primary breast cancer from 1995 to 2005 (n=9300), using hospital discharge registry data to quantify comorbidities by Charl
Besides chemotherapy drugs, Nanodrugs, traditional Chinese medicine (TCM) and ICIs also induce ICD, boosting immune response. ICIs, like PD-1/PD-L1 inhibitors, revolutionize cancer treatment but face limited success in cold tumors. Thus, ICD induction combined with ICIs is studied extensively for ...
Enhanced neovasculogenesis, especially vasculogenic mimicry (VM), contributes to the development of triple-negative breast cancer (TNBC). Breast tumor-initiating cells (BTICs) are involved in forming VM; however, the specific VM-forming BTIC population a
Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer 来自 dx.doi.org 喜欢 0 阅读量: 84 作者:X Qiu,Y Qu,B Guo,H Zheng,F Meng,Z Zhong 摘要: α5β1-targeted micellar paclitaxel (ATN-MPTX) shows high selectivity and strong ICD in murine 4T1 ...
Breast cancer remains a major public health problem, with approximately 40,000 US women dying annually. The continuing controversy surrounding the most effective strategy for deploying the various available technologies continues unabated, and clear consensus is lacking on when to screen, how often, ...
Findings In this phase 1 nonrandomized clinical trial of 66 patients with advanced-stage ERBB2-positive breast cancer, a majority grade 1/2 adverse events were generated for all doses. Patients in arms 2 (100 μg) and 3 (500 μg) had higher magnitude ICD T-cell levels than those in ...
Screen-detected patients living in rural areas also had a longer diagnostic interval. Having a regular primary care provider was not associated with a shorter diagnostic interval. Abstract The cancer diagnostic process can be protracted, and it is a time of great anxiety for patients. The ...